AUA 2018

AUA 2018: The German Risk-Adapted Prostate Cancer Screening Trial (PROBASE) – First Results After Recruitment of 30,000 Men

San Francisco, CA (UroToday.com) Population-based PSA screening is a controversial issue. A risk-adapted approach using a baseline PSA value at age 45 may improve the number needed to screen and to treat. The German risk-adapted PCa screening trial PROBASE is currently the largest ongoing screening trial and aims to accrue 50,000 men within 5 yrs in a prospective and randomized fashion. The trial opened in April 2014. 

AUA 2018: The Association Between Physician Trust and Prostate Specific Antigen Screening: Implications for Shared Decision Making

San Francisco, CA (UroToday.com) Most cancer organizations recommend shared decision making for PSA screening, a process relying on a trusting relationship between patient and physician. The objective of this study was to assess the degree to which an individual’s trust in cancer information from their physician compared to internet based information, impacts the likelihood of receiving PSA-screening. 

AUA 2018: Temperature Elevation During High-Power Holmium Laser Lithotripsy in an In Vivo Porcine Model

San Francisco, CA USA (UroToday.com) Ali Aldoukhi, MD, clinical urologist from the University of Michigan, Ann Arbor, MI, presented his data on the photothermal effect of holmium laser stone fragmentation. Aldoukhi and his team of researchers wanted to determine safe parameters of laser lithotripsy with intraoperative effects within a porcine model. They used previous in vitro studies, which showed that increased temperature to renal tissue does cause injury, as their inspiration to pursue this research question.

AUA 2018: PROSPER Study Results: Impact of Enzalutamide on Pain and Health-Related Quality of Life in Men with nmCRCP

San Francisco, CA (UroToday.com) The PROSPER trial (NCT02003924) compared the efficacy and safety of enzalutamide (ENZA) 160 mg/day vs placebo (PBO) in asymptomatic men with non-metastatic castration-resistant prostate cancer with prostate-specific antigen doubling time of 10 months. Patients were randomized 2:1. The study showed a statistically significant improvement in metastasis-free survival (MFS) with ENZA vs PBO. PROSPER also prospectively evaluated health-related quality of life (HRQoL) and pain.

AUA 2018: Intraoperative Console Display and Control of Anatomical Renderings During Robot-Assisted Laparoscopic Partial Nephrectomy

San Francisco, CA USA (UroToday.com) Steven Monda, fourth year medical student from Washington University in St. Louis, presented his center’s research study on the integration of three dimensional (3D), virtual reality (VR) models during robot assisted partial nephrectomy. The inspiration of this research project stemmed from the increased prevalence of 3D renderings during perioperative surgical planning.

AUA 2018: Cardiovascular Events and Biomarkers in a Randomized Trial Comparing LHRH Agonist and Antagonist Among Patients with Advanced Prostate Cancer

San Francisco, CA (UroToday.com) Androgen-deprivation therapy (ADT) used in prostate cancer patients may increase their risk of cardiovascular events. There has been data suggesting that LHRH-antagonist may be associated with lower risk of these events compared to LHRH agonists. The authors hypothesized a role for FSH in mediating ADT induced atherosclerosis. In this current presentation, the authors report biomarkers of cardio-vascular events and outcomes from a randomized controlled study.

AUA 2018: The Effectiveness and Safety of Cabazitaxel in Patients with mCRPC in Routine Clinical Practice: Results of CAPRISTANA

San Francisco, CA (UroToday.com) Cabazitaxel (CBZ) is approved for patients with mCRPC previously treated with docetaxel. This study reports on the observed effectiveness and safety of CBZ in routine clinical practice.